动态重编程的瘤免疫网络通过多循环检查点退化癌症免疫治疗
Tao Shi1, Yuanyuan Wu2, Yiran Cai1
1Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
概括
一个新的RECYC平台清除了像PD-L1这样的瘤和髓状细胞上的免疫检查点. 这种方法将免疫抑制性瘤微环境 (TIME) 转化为免疫刺激状态,增强抗瘤免疫力并改善免疫治疗反应.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 生物技术是生物技术.
背景情况:
- 免疫检查点阻塞的有效性受到免疫抑制性瘤免疫微环境 (TIME) 的限制.
- 当前的细胞外向蛋白质降解方法不能完全解决 TIME 中免疫检查点的复杂性.
- 多细胞分布和免疫检查点的交叉交互对癌症治疗构成挑战.
研究的目的:
- 开发一个新的平台,在时间内持续免疫检查点清除.
- 研究RECYC在重编程瘤免疫网络中的潜力.
- 为了增强抗瘤免疫力和改善免疫治疗结果.
主要方法:
- 开发一个受体介导的内分泌体循环回收合体 (RECYC) 平台.
- 使用CI-M6PR向的阿巴和对pH反应的蛋白质结合用于检查点清除.
- 在ex vivo共同培养和in vivo小鼠模型中测试RECYC,包括免疫冷和免疫热癌症模型.
主要成果:
- RECYC有效地消除了瘤细胞和髓状细胞 (巨细胞,中性粒细胞,树突细胞) 上的编程死亡配体1 (PD-L1) 表达.
- RECYC将TIME从免疫抑制转化为免疫刺激,增强CD8+T细胞的反应.
- 在小鼠癌症模型中,与PD-L1阻断相比,RECYC显示出优异的抗瘤作用.
结论:
- 该RECYC平台提供了一个有效的回收和广泛的免疫检查点清除在时间的有效策略.
- RECYC重新编程多细胞瘤免疫网络,从而产生持久的免疫疗法反应.
- 这种方法有望克服当前癌症免疫疗法的局限性.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Cancer Stem Cells and Tumor Maintenance
6.2K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.2K


